Abstract
16α-18F-fluoroestradiol (18F-FES) has been developed as a promising positron emission tomography (PET) imaging agent for targeting estrogen receptor positive (ER+) breast cancer in the clinical trial. However, the radiosynthesis of 18F-FES often requires two steps and tough experimental conditions. Therefore, a new estradiol derivative (18F-AmBF3-ES) was prepared by an efficient one-step 18F-radiolabeling method. The tracer was obtained in high yield (~65%) and excellent radiochemical purity (>98%) within 30 min. The uptake rate of 18F-AmBF3-ES in ER+ cells was about 3.5% at 30 min. The results suggested that the tracer may be a potential PET imaging agent for ER+ breast cancer.
Similar content being viewed by others
References
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108
Linden HM, Dehdashti F (2013) Novel methods and tracers for breast cancer imaging. Semin Nucl Med 43:324–329
Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474–1481
Fowler AM, Chan SR, Sharp TL, Fettig NM, Zhou D, Dence CS, Carlson KE, Jeyakumar M, Katzenellenbogen JA, Schreiber RD, Welch MJ (2012) Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer. J Nucl Med 53:1119–1126
Zhou D, Lin M, Yasui N, Al-Qahtani MH, Dence CS, Schwarz S, Katzenellenbogen JA (2014) Optimization of the preparation of fluorine-18-labeled steroid receptor ligands 16alpha-[18F]fluoroestradiol (FES), [18F]fluoro furanyl norprogesterone (FFNP), and 16beta-[18F]fluoro-5alpha-dihydrotestosterone (FDHT) as radiopharmaceuticals. J Label Compd Radiopharm 57:371–377
Katzenellenbogen JA (1995) Designing steroid receptor-based radiotracers to image breast and prostate tumors. J Nucl Med 36(suppl 6):8S–13S
Enginar H, Ünak P, Yurt F, Biber FZ (2002) An oestrogen-derivative labeled with 99mTc and its radiopharmaceutical potential. J Radioanal Nucl Chem 251:473–479
Biber FZ, Unak P, Enginar H, Ertay T, Medine EI, Tasci C, Durak H (2005) Synthesis of DTPA-attached estradiol derivative and determination of its radiopharmaceutical potential. J Radioanal Nucl Chem 266:445–454
Xia X, Feng H, Li C, Qin C, Song Y, Zhang Y, Lan X (2016) 99mTc-labeled estradiol as an estrogen receptor probe: preparation and preclinical evaluation. Nucl Med Biol 43:89–96
Brodack JW, Kilbourn MR, Welch MJ (1988) Automated production of several positron-emittingradiopharmaceuticals using a single laboratory robot. Appl Radiat Isot 39:689–698
Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, Petra PH, Peterson LM, Schubert EK, Dunnwald LK, Krohn KA, Mankoff DA (2006) Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 24:2793–2799
Mortimer JE, Dehdashti F, Siegel BA, Katzenellenbogen JA, Fracasso P, Welch MJ (1996) Positron emission tomography with 2-[18F]fluoro-2-deoxy-Dglucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 2:933–939
McGuire AH, Dehdashti F, Siegel BA, Lyss AP, Brodack JW, Mathias CJ, Mintun MA, Katzenellenbogen JA, Welch MJ (1991) Positron tomographic assessment of 16α-[18F]Fluoro-17/3-estradiol uptake in metastatic breast carcinoma. J Nucl Med 32:1526–1531
Oude Munnink TH, Nagengast WB, Brouwers AH, Schroder CP, Hospers GA, Lub-de Hooge MN, van der Wall E, van Diest PJ, de Vries EG (2009) Molecular imaging of breast cancer. Breast 18(suppl 3):S66–S73
Kiesewetter DO, Kilbourn MR, Landvatter SW, Heiman DF, Katzenellenbogen JA, Welch MJ (1984) Preparation of four fluorine-18-labeled estrogensand their selective uptakes in target tissues of immature rat. J Nucl Med 25:1212–1221
Brodack JW, Kilbourn MR, Welch MJ, Katzenellenbogen JA (1986) Application of robotics to radiopharmaceutical preparation: controlled synthesis of fluorine-18 16α-fluoroestradiol-17β. J Nucl Med 27:714–721
Mintun MA, Welch MJ, Siegel BA, Mathias CJ, Brodack JW, McGuire AH, Katzenellenbogen JA (1988) Breast cancer PET imaging of estrogen receptors. Radiology 169:45–48
Romer J, Fuchtner F, Steinbach J, Johannsen B (1999) Automated production of 16α-[18F]Fluoroestradiol for breast cancer imaging. Nucl Med Biol 26:473–479
Knott KE, Grätz D, Hübner S, Jüttler S, Zankl C, Müller M (2011) Simplified and automatic one-pot synthesis of 16α-[18F]fluoroestradiol without high-performance liquid chromatography purification. J Label Compd Radiopharm 54:749–753
Oh SJ, Chi DY, Mosdzianowski C, Kil HS, Ryu JS, Moon DH (2007) The automatic production of 16alpha-[18F]fluoroestradiol using a conventional [18F]FDG module with a disposable cassette system. Appl Radiat Isot 65:676–681
Kil HS, Cho HY, Lee SJ, Oh SJ, Chi DY (2013) Alternative synthesis for the preparation of 16alpha-[(18) F]fluoroestradiol. J Label Compd Radiopharm 56:619–626
Liu Z, Lin KS, Benard F, Pourghiasian M, Kiesewetter DO, Perrin DM, Chen X (2015) One-step (18)F labeling of biomolecules using organotrifluoroborates. Nat Protoc 10:1423–1432
Liu Z, Pourghiasian M, Radtke MA, Lau J, Pan J, Dias GM, Yapp D, Lin KS, Benard F, Perrin DM (2014) An organotrifluoroborate for broadly applicable one-step 18F-labeling. Angew Chem Int Ed Engl 53:11876–11880
Pourghiasian M, Liu Z, Pan J, Zhang Z, Colpo N, Lin KS, Perrin DM, Benard F (2015) (18)F-AmBF3-MJ9: a novel radiofluorinated bombesin derivative for prostate cancer imaging. Bioorg Med Chem 23:1500–1506
Liu Z, Pourghiasian M, Benard F, Pan J, Lin KS, Perrin DM (2014) Preclinical evaluation of a high-affinity 18F-trifluoroborate octreotate derivative for somatostatin receptor imaging. J Nucl Med 55:1499–1505
Liu Z, Radtke MA, Wong MQ, Lin KS, Yapp DT, Perrin DM (2014) Dual mode fluorescent (18)F-PET tracers: efficient modular synthesis of rhodamine-[cRGD]2-[(18)F]-organotrifluoroborate, rapid, and high yielding one-step (18)F-labeling at high specific activity, and correlated in vivo PET imaging and ex vivo fluorescence. Bioconjug Chem 25:1951–1962
Aucagne V, Valverde IE, Marceau P, Galibert M, Dendane N, Delmas AF (2012) Towards the simplification of protein synthesis: iterative solid-supported ligations with concomitant purifications. Angew Chem Int Ed Engl 51:11320–11324
Li H, Aneja R, Chaiken I (2013) Click chemistry in peptide-based drug design. Molecules 18:9797–9817
Zhu C, Xu Q, Pan D, Xu Y, Liu P, Yang R, Wang L, Sun X, Luo S, Yang M (2016) Prostate cancer imaging of FSHR antagonist modified with a hydrophilic linker. Contrast Media Mol Imaging 11:99–105
Leeson PD, Springthorpe B (2007) The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 6:881–890
Leo AH, Hansch C, Elkins D (1971) Partition coefficients and their uses. Chem Rev 71(6):525–616
Sukerkar PA, MacRenaris KW, Meade TJ, Burdette JE (2011) A steroid-conjugated magnetic resonance probe enhances contrast in progesterone receptor expressing organs and tumors in vivo. Mol Pharm 8:1390–1400
Liu Y, Miao Q, Zou P, Liu L, Wang X, An L, Zhang X, Qian X, Luo S, Liang G (2015) Enzyme-controlled intracellular self-assembly of (18)F nanoparticles for enhanced MicroPET imaging of tumor. Theranostics 5:1058–1067
Huang R, Wang X, Wang D, Liu F, Mei B, Tang A, Jiang J, Liang G (2013) Multifunctional fluorescent probe for sequential detections of glutathione and caspase-3 in vitro and in cells. Anal Chem 85:6203–6207
Aliaga A, Rousseau JA, Ouellette R, Cadorette J, van Lier JE, Lecomte R, Benard F (2004) Breast cancer models to study the expression of estrogen receptors with small animal PET imaging. Nucl Med Biol 31:761–770
Okamoto M, Naka K, Kitagawa Y, Ishiwata K, Yoshimoto M, Shimizu I, Toyohara J (2015) Synthesis and evaluation of 7alpha-(3-[(18)F]fluoropropyl) estradiol. Nucl Med Biol 42:590–597
Qin C, Lan X, He J, Xia X, Tian Y, Pei Z, Zhang Y (2013) An in vitro and in vivo evaluation of a reporter gene/probe system hERL/18F-FES. Plos One 8:e61911
Acknowledgements
This work was financially supported by Natural Science Foundation of China (21371082), Natural Science Foundation of Jiangsu Province (BK20141102 and BK20151118) and Key Medical Talent Project of Jiangsu Province (RC2011097).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Liu, G., Wang, W., Lin, J. et al. Kit-like 18F-labeling of an estradiol derivative as a potential PET imaging agent for estrogen receptor-positive breast cancer. J Radioanal Nucl Chem 312, 599–607 (2017). https://doi.org/10.1007/s10967-017-5245-7
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10967-017-5245-7